Status:

COMPLETED

Aripiprazole and Lexapro Drug Interaction Study

Lead Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions:

Healthy

Eligibility:

All Genders

18-45 years

Phase:

PHASE1

Brief Summary

The purpose of this clinical research study is to learn whether aripiprazole has effect on the steady-state pharmacokinetics of escitalopram in healthy subjects. The safety and tolerability of aripipr...

Eligibility Criteria

Inclusion

  • Healthy male and female subjects, ages 18 to 45. (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study in such a manner that the risk of pregnancy in minimized.
  • Body Mass Index (BMI) of 18 to 33 kg/m2 inclusive.

Exclusion

  • Subjects with a decrease in SBP of \>=20 mm Hg and increase in HR of \>=20 bpm after 2 minutes standing vs. 2 minutes supine at screening or with frank orthostatic hypotension at screening.
  • Supine BP of 90/50 mm Hg or lower at screening.

Key Trial Info

Start Date :

August 1 2006

Trial Type :

INTERVENTIONAL

End Date :

November 1 2006

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT00361790

Start Date

August 1 2006

End Date

November 1 2006

Last Update

November 8 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Local Institution

Lenexa, Kansas, United States